Contract Notice Detail
Summary Information
Summary Information
Base Total Price:
23,823.816000 Euro
Request Reference:
CPR 23/2024
Request Name:
Aquisição de medicamentos antirretrovíricos para tratamento da infeção por VIH
Phase:
Tendering Phase
State:
Awarded
Description:
Aquisição de medicamentos antirretrovíricos para tratamento da infeção por VIH
Procedure Type:
VortalGOV - Acquisition under a Framework Agreement (via Direct Award)
Lot Name
Lot Base Price
Expected Duration
A2 - ABACAVIR [300MG; CÁP/COMP]
-
18
(
Months
)
A729 - ABACAVIR + LAMIVUDINA (Comp.Revest.)[600 + 300 MG; COMP]
-
18
(
Months
)
D568 - DORAVIRINA [100 MG; COMP]
-
18
(
Months
)
L27 - LAMIVUDINA (SOL.ORAL) [10 MG/ML; FRS]
-
18
(
Months
)
L349 - LAMIVUDINA (comp. revestidos) [300 MG; COMP]
-
18
(
Months
)
R59 - RITONAVIR [100MG; CÁP/COMP]
-
18
(
Months
)
Object of the Contract
Object of the Contract
Type of Contract:
Supplies Acquisition
Main Object CPV Main Category:
Quinta do Alvito 6200-251 Covilhã Castelo Branco PORTUGAL
CPV Main Vocabulary
33600000-6 - Pharmaceutical products
CPV Supplementary Vocabulary
Additional Classifications List
Scheduling
Scheduling
Request online publishing date:
6/7/2024 4:37 PM
(UTC +1 hour)
National official publishing date and time (DR):
1/19/2022 12:00 AM
(UTC 0 hours)
Due datetime for receiving replies:
6/18/2024 5:00 PM
(UTC +1 hour)
Financial Settings
Financial Settings
Define Warranties?
No
Contract Documents
Contract Documents
Document Name
Description
Doc Classification
CPR 23-2024 Convite.pdf
CPR 23-2024 Convite.pdf
Download
Object of contract
This contract is subject to renewal?
No
The procurement is related to a project and/or programme financed by European Union funds?
No
Legal, economic, financial and technical information
The contract is reserved to sheltered workshops and economic operators aiming at the social and professional integration of disabled or disadvantaged persons?
No
Questionnaire
Questionnaire
1
Lot Title
A2 - ABACAVIR [300MG; CÁP/COMP]
Base Price
4 107,000000
1.1
Bill of Quantities
*
This price list has extra requirements. Make sure everything is completed, under each article line.
Item Code
Description
Quantity
Unit
A2
ABACAVIR [300MG; CÁP/COMP]
2 220,000000
NXTWY.UMT.13315
Buyer Comment:
502248793 | Mylan, Lda. | CPA:2022040/120/0072 | NºAIM:5733902; 508107997 | Generis Farmacêutica, S.A. | CPA:2022040/263/0030 | NºAIM:5782214;
TOTAL
(The amounts shown do not include VAT)
2
Lot Title
A729 - ABACAVIR + LAMIVUDINA (Comp.Revest.)[600 + 300 MG; COMP]
Base Price
6 726,000000
2.1
Bill of Quantities
*
This price list has extra requirements. Make sure everything is completed, under each article line.
Item Code
Description
Quantity
Unit
A729
ABACAVIR + LAMIVUDINA (Comp.Revest.)[600 + 300 MG; COMP]
1 770,000000
NXTWY.UMT.13315
Buyer Comment:
502248793 | Mylan, Lda. | CPA:2022040/120/0074 | NºAIM:5730262; 508107997 | Generis Farmacêutica, S.A. | CPA:2022040/263/0029 | NºAIM:5690615;
TOTAL
(The amounts shown do not include VAT)
3
Lot Title
D568 - DORAVIRINA [100 MG; COMP]
Base Price
8 693,916000
3.1
Bill of Quantities
*
This price list has extra requirements. Make sure everything is completed, under each article line.
Item Code
Description
Quantity
Unit
D568
DORAVIRINA [100 MG; COMP]
1 320,000000
NXTWY.UMT.13315
Buyer Comment:
500191360 | Merck Sharp & Dohme, Lda. | CPA:2022040/193/0041 | NºAIM:5763818;
TOTAL
(The amounts shown do not include VAT)
4
Lot Title
L27 - LAMIVUDINA (SOL.ORAL) [10 MG/ML; FRS]
Base Price
588,000000
4.1
Bill of Quantities
*
This price list has extra requirements. Make sure everything is completed, under each article line.
Item Code
Description
Quantity
Unit
L27
LAMIVUDINA (SOL.ORAL) [10 MG/ML; FRS]
35,000000
NXTWY.UMT.13315
Buyer Comment:
509117961 | ViiVHIV Healthcare, Unipessoal, Lda. | CPA:2022040/634/0020 | NºAIM:2425585;
TOTAL
(The amounts shown do not include VAT)
5
Lot Title
L349 - LAMIVUDINA (comp. revestidos) [300 MG; COMP]
Base Price
1 728,000000
5.1
Bill of Quantities
*
This price list has extra requirements. Make sure everything is completed, under each article line.
Item Code
Description
Quantity
Unit
L349
LAMIVUDINA (comp. revestidos) [300 MG; COMP]
3 600,000000
NXTWY.UMT.13315
Buyer Comment:
501505334 | Farmoz - Soc. Técnico Medicinal, S.A. | CPA:2022040/46/0065 | NºAIM:5620323; 502248793 | Mylan, Lda. | CPA:2022040/120/0081 | NºAIM:5418322; 507045491 | Teva Pharma - Produtos Farmacêuticos, Lda. | CPA:2022040/334/0100 | NºAIM:5321864; 508107997 | Generis Farmacêutica, S.A. | CPA:2022040/263/0037 | NºAIM:5483466;
TOTAL
(The amounts shown do not include VAT)
6
Lot Title
R59 - RITONAVIR [100MG; CÁP/COMP]
Base Price
1 980,900000
6.1
Bill of Quantities
*
This price list has extra requirements. Make sure everything is completed, under each article line.
Item Code
Description
Quantity
Unit
R59
RITONAVIR [100MG; CÁP/COMP]
6 390,000000
NXTWY.UMT.13315
Buyer Comment:
501505334 | Farmoz - Soc. Técnico Medicinal, S.A. | CPA:2022040/46/0068 | NºAIM:5678123; 502248793 | Mylan, Lda. | CPA:2022040/120/0102 | NºAIM:5732540; 508107997 | Generis Farmacêutica, S.A. | CPA:2022040/263/0103 | NºAIM:5821269; 510229050 | AbbVie, Lda. | CPA:2022040/694/0095 | NºAIM:5267216;
TOTAL
(The amounts shown do not include VAT)
Evaluation
Evaluation
Vision
Avaliação
Definir modelo de avaliação
Sim
Não
Modalidade de avaliação
Selecione…
Monofator
Método de Avaliação
Selecione…
Manual
Divulgar critérios de avaliação
Sim
Não
Critérios da Avaliação
1 - A2 - ABACAVIR [300MG; CÁP/COMP]
Critérios da Avaliação
Descrição
Tipo de Fator
Peso (%)
1.
Preço
Preço
100%
Normas de desempate
Definir normas de desempate?
Sim
Não
2 - A729 - ABACAVIR + LAMIVUDINA (Comp.Revest.)[600 + 300 MG; COMP]
Critérios da Avaliação
Descrição
Tipo de Fator
Peso (%)
1.
Preço
Preço
100%
Normas de desempate
3 - D568 - DORAVIRINA [100 MG; COMP]
Critérios da Avaliação
Descrição
Tipo de Fator
Peso (%)
1.
Preço
Preço
100%
Normas de desempate
4 - L27 - LAMIVUDINA (SOL.ORAL) [10 MG/ML; FRS]
Critérios da Avaliação
Descrição
Tipo de Fator
Peso (%)
1.
Preço
Preço
100%
Normas de desempate
5 - L349 - LAMIVUDINA (comp. revestidos) [300 MG; COMP]
Critérios da Avaliação
Descrição
Tipo de Fator
Peso (%)
1.
Preço
Preço
100%
Normas de desempate
6 - R59 - RITONAVIR [100MG; CÁP/COMP]
Critérios da Avaliação
Descrição
Tipo de Fator
Peso (%)
1.
Preço
Preço
100%
Normas de desempate
Public Messages
Public Messages
Type
Reference
Subject
Date
No items found...